Skillsoft Corp. Form 8-K Summary
Business Context and Reporting Period
Skillsoft Corp. (NYSE: SKIL) filed a Current Report on Form 8-K dated March 26, 2026, regarding a notice of noncompliance with New York Stock Exchange (NYSE) listing standards. The report addresses deficiencies identified as of March 25, 2026, and October 31, 2025.
Key Financial Metrics
- Market Capitalization: The 30 trading-day average market capitalization was less than $50 million as of March 25, 2026.
- Stockholders' Equity: The last reported stockholder's equity was less than $50 million as of October 31, 2025.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
The Company received a notice from the NYSE stating it is not in compliance with Section 802.01B of the NYSE Listed Company Manual due to the market capitalization and stockholder's equity deficiencies noted above. This represents a material change in the Company's listing status, triggering a cure period.
Outlook, Management Commentary, and Risks
- Cure Period: Skillsoft has 18 months to cure the deficiencies, subject to NYSE approval of a business plan.
- Business Plan: The Company intends to submit a business plan within 45 calendar days of receiving the notice to demonstrate its ability to regain compliance.
- Trading Status: Common stock will continue to be listed and traded on the NYSE during the cure period, subject to quarterly review.
- Operations: Management states the noncompliance does not affect ongoing business operations or SEC reporting requirements.
- Risks: Forward-looking statements highlight risks regarding the ability to submit an acceptable business plan, NYSE acceptance of the plan, and the ability to maintain the listing.
Investor Verification Checklist
- Verify the specific stock price and trading volume trends leading to the sub-$50 million market cap average.
- Review the most recent 10-Q or 10-K to confirm the exact stockholders' equity figure as of October 31, 2025.
- Monitor the submission of the Company's business plan to the NYSE within the 45-day window.
- Track quarterly NYSE reviews to ensure no further delisting notices are issued during the cure period.